Collagenase clostridium histolyticum
is a proteinase that hydrolyzes collagen, resulting in destruction of collagen deposits.
Takaso, "Enhancement of periosteal bone formation by basic fibroblast-derived growth factor containing polycystic kidney disease and collagen-binding domains from Clostridium histolyticum
collagenase," Journal of Tissue Engineering and Regenerative Medicine, 2015.
A variety of other medications have been used for intralesional injection, including verapamil, nicardipine, interferon alpha-2b, and more recently, collagenase clostridium histolyticum
(CCH) (Jordan et al., 2014) Only collagenase Clostridium histolyticum
is FDA-approved for intralesional injection for treatment of PD.
Xiapex (collagenase clostridium histolyticum
), is a pharmacological treatment for Dupuytren's contracture and may be an alternative to invasive and often complicated surgery for patients.
b) Probiotic supplementation was associated with reduced excessive crying, increased stool frequency and reduced Clostridium histolyticum
The FDA's Arthritis Advisory Committee voted 12-0 that the treatment, collagenase Clostridium histolyticum
, should be approved for treating advanced Dupuytren's, based on the available safety and efficacy data.
The formulation, made up of two collagenases naturally produced by the bacterium Clostridium histolyticum
, is injected into the cord at 4-week intervals, for a maximum of three injections), according to the manufacturer, Auxilium Pharmaceuticals Inc.
Endo International announced that it will present new data showing collagenase clostridium histolyticum
significantly met the clinical endpoint of improved cellulite severity and appearance and was well tolerated in recent Phase 3 clinical trials.
Biopharmaceutical company BioSpecifics Technologies (NasdaqGM:BSTC) reported on Monday the receipt of approval for XIAFLEX (collagenase clostridium histolyticum
) for the treatment of patients with Dupuytren's contracture in Japan.
Pa., has announced that The Journal of Hand Surgery (JHS) has published in its December online edition the company's pivotal CORD II phase III clinical trial of XIAFLEX[R] (collagenase clostridium histolyticum
), a novel, first-in-class biologic for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord.
Wainwright analyst Raghuram Selvaraju raised his price target for BioSpecifics Technologies (BSTC) to $81 after Endo International (ENDP) reported positive results from two identical Phase 3 trials of Collagenase Clostridium Histolyticum
, or Xiaflex, for the treatment of cellulite.